• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ketryx Announces DeepHealth Selected Its Software to Accelerate AI-Powered Health Informatics Innovation

    12/4/24 1:30:00 PM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email

    CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Ketryx announced today that DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), has selected Ketryx to accelerate the delivery of AI-powered health informatics solutions. DeepHealth's solutions leverage a cloud-native operating system to drive operational efficiency, improved clinical confidence, and better care delivery. According to the FDA, radiology leads the way in AI/ML adoption within the SaMD sector, with 79% of newly approved devices in the field using these technologies to enhance diagnostics and patient care.

    Ketryx is the first and only AI-enabled connected application lifecycle management platform for the life sciences industry

    "We are harnessing the power of AI to tackle clinical and operational challenges that arise in complex, high-volume care settings, with the aim of enabling better outcomes," said Sham Sokka, RadNet's Chief Operating and Technology Officer for Digital Health. "We envision an integrated radiology workflow that eliminates operational silos, ensuring the right data is available at the right time for everyone in the care team. The Ketryx software enables us to scale our innovation with quality through a single streamlined software development lifecycle, helping us expedite releases."

    "We are honored to support DeepHealth as they revolutionize radiology with their leading artificial intelligence-driven solutions," said Ketryx CEO and founder Erez Kaminski. "With Ketryx, DeepHealth is well positioned to meet the challenges of scaling rapidly with automation while prioritizing patient safety and care."

    Transforming Complex Radiology Workflows for Patient Outcomes

    The radiology workflow is fragmented, involving multiple systems, tools, and stakeholders. This complex interplay creates challenges on several fronts, including patient engagement, technology integration, workforce management, and clinical outcomes. As radiology's role in healthcare expands amid growing economic pressure and staff shortages, a transformative shift in informatics is essential to keep pace. DeepHealth is driving this transformation through its cloud-native operating system that unifies data across clinical and operational workflows and personalizes AI-powered workspaces for everyone in the care team.

    Leveraging the Ketryx Connected Lifecycle Management for Scale

    To achieve this ambitious transformation, DeepHealth turned to Ketryx. By leveraging Ketryx's connected lifecycle management software, DeepHealth can accelerate product development, deliver the latest technology at scale, and meet specific customer needs while ensuring quality and compliance. DeepHealth has also used Ketryx to employ a microservice architecture that allows the company to easily integrate AI advancements, accelerating development cycles.

    Automating Documentation and Traceability From Preferred Development Tools

    By leveraging Ketryx, DeepHealth can automate documentation and ensure end-to-end traceability across preferred developer tools already in use, like Jira and GitLab. This integration enables both R&D and Quality teams to accelerate the delivery of innovative products to market. In addition to enhancing DeepHealth's ability to develop software faster, Ketryx also ensures that its AI-powered solutions remain aligned with evolving regulatory requirements.

    For more information about DeepHealth and Ketryx, visit DeepHealth.com and Ketryx.com.

    About Ketryx

     Ketryx is the first and only AI-enabled connected application lifecycle management platform for the life sciences industry. Our automation-based software enables companies building FDA-regulated software and AI/ML-based applications to accelerate development through modern cloud-based tools while improving quality and compliance. With a risk-based generative AI framework, Ketryx is built to safely streamline and accelerate your regulated process functions with fine-grained output control and a human-in-the-loop approval process. Ketryx creates a real-time, and traceable, single source of truth by overlaying product development tools and connecting all items, risks, code, and tests. Teams reduce their time to market with automated documentation and improve their quality and compliance through the enforcement of SOPs across connected systems. Learn more at ketryx.com.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ketryx-announces-deephealth-selected-its-software-to-accelerate-ai-powered-health-informatics-innovation-302321708.html

    SOURCE Ketryx

    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Which company has selected Ketryx to accelerate AI-powered health informatics?

      DeepHealth, Inc. has chosen Ketryx to enhance the delivery of AI-powered health informatics solutions.

    • What role will Ketryx play in DeepHealth's operations?

      Ketryx will help DeepHealth achieve an integrated radiology workflow and streamline software development to improve operational efficiency.

    • What technology does DeepHealth use to drive its AI-powered health informatics solutions?

      DeepHealth's solutions utilize a cloud-native operating system to unify clinical and operational workflows, improving patient care and operational efficiency.

    • What does the FDA indicate about AI/ML adoption in the radiology sector?

      The FDA reports that 79% of newly approved devices in radiology are utilizing AI/ML to enhance diagnostics and patient care.

    • How does Ketryx enhance DeepHealth's product development and compliance process?

      Ketryx's software allows for the automation of documentation and end-to-end traceability across development tools, ensuring quality and compliance in product delivery.

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $RDNT
    SEC Filings

    View All

    SEC Form 10-K filed by RadNet Inc.

    10-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 5:17:51 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 7:01:44 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    3/2/26 7:00:48 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DeepHealth Unveils Industry's Most Comprehensive Portfolio of Native Clinical AI Solutions at ECR 2026

    VIENNA, March 04, 2026 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities — MR, CT, X-ray, Mammography and Ultrasound — and spanning detection, assessment and monitoring, all available on one platform. With this week's acquisition of Gleamer, DeepHealth further expands its leadership in advancing screening tools into routine imaging and acute diagnostic care, uniquely positioned to deliver the next era of AI-powered health informatics.  "As European na

    3/4/26 7:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /CNW/ -- USANewsGroup.com News Commentary -- AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Butterfly Network (NYSE:BFLY), Tempus AI (NASDAQ:TEM), RadNet (NASDAQ:RDNT), and GE HealthCare (NASDAQ:GEHC) are conv

    3/3/26 12:19:00 PM ET
    $BFLY
    $GEHC
    $RDNT
    Medical Electronics
    Health Care
    Medical Specialities
    Computer Software: Programming Data Processing

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP of Fin Planning, CAO Patel Mital was granted 20,667 shares, increasing direct ownership by 12% to 200,175 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:14 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Pres & CEO, Digital Health Wesdorp Cornelis was granted 20,330 shares, increasing direct ownership by 38% to 73,825 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:10 PM ET
    $RDNT
    Medical Specialities
    Health Care

    EVP and Chief Legal Officer Katz David Jeffrey was granted 19,289 shares, increasing direct ownership by 27% to 90,866 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    3/5/26 4:15:12 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Reports Fourth Quarter 2025 Results, Including Record Revenue and Adjusted EBITDA⁽¹⁾ and Releases 2026 Financial Guidance

    Total Company Revenue increased 14.8% to a quarterly record of $547.7 million in the fourth quarter of 2025 from $477.1 million in the fourth quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 48.2% to $27.9 million in the fourth quarter of 2025 from $18.9 million in the fourth quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $87.7 million in the fourth quarter of 2025 as compared with $75.0 million in the fourth quarter of 2024, an increase of 16.9%; Digital Health reportable segment Adjusted EBITDA(1) increased 8.9% to $4.9 million in the fourth quarter of 2025 from $4.5 million in the fourth quarter of

    3/2/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Acquires Gleamer, Making RadNet's DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide

    Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications.Gleamer's leadership in routine imaging, and particularly X-ray, is unparalleled through the breadth and scale of its cloud-first AI solutions. DeepHealth, combined with Gleamer's solutions will provide the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities. Gleamer achieved an Annual Recurring Revenue ("ARR") i compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 millio

    3/2/26 5:45:00 AM ET
    $RDNT
    Medical Specialities
    Health Care